Nagase and Craif Partnership
2025-06-11 01:27:10

Nagase Industries Partners with Craif for Next-Gen Business Development and Knowledge Acquisition

Nagase Industries Forms Strategic Alliance with Craif



On June 11, 2025, Nagase Industries Co., Ltd., headquartered in Chiyoda, Tokyo, under the leadership of President Hiroyuki Ueshima, has announced a significant capital and business partnership with Craif Co., Ltd. This collaboration aims to lay the groundwork for future business development by acquiring knowledge in areas defined by their mid-term management plan, ACE 2.0, which emphasizes the pillars of "Foundation," "Focus," "Nurturing," and "Improvement."

This partnership marks the first investment project through their newly established corporate venture capital fund, Nagase Future Investments, created in April 2025. The collaboration is expected to accelerate the utilization of the fund and enhance efforts related to innovation and technology advancement.

Craif, also based in Tokyo, is at the forefront of developing cutting-edge urine testing services that utilize proprietary technology to analyze microRNA (miRNA) found in urine. Their premier product, My Signal Scan, allows for ultra-early detection of various cancers, including pancreatic cancer and up to six other types, providing high-precision results by accurately identifying cancer occurrence at its early stages. This innovative testing solution is already being provided to more than 1,000 medical institutions and private individuals across Japan, showcasing its growing presence in the healthcare market.

As Craif continues to establish its track record, it aims to obtain approval for its medical devices while exploring expansion into the U.S. market for sustained growth. The partnership with Nagase Industries will further strengthen Craif’s commitment to advancing early disease detection and personalized medicine.

Craif Overview


  • - Company Name: Craif Co., Ltd.
  • - Headquarters: Bunkyo, Tokyo
  • - CEO: Takamitsu Onose
  • - Business Outline: Focused on research and development of next-generation tests for early disease detection and personalized medicine, notably through its urine cancer test, My Signal.
  • - Website: craif.com

Contact Information


For business inquiries regarding this partnership, please reach out to Nagase Future Investments at cvc@nagase.co.jp.
For press-related inquiries, contact the Corporate Relations Department at Nagase Industries at TEL: 070-4314-0671.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.